ERBB2 and breast carcinoma: In the clinical literature, the immunohistochemically defined 'triple-negative' (TN) (ER, progesterone receptor (PR), and HER2) class has generated considerable interest given their poor prognosis, an association with hereditary tumors, and the lack of established therapies that target this subtype of breast cancer.